Production approval of flucloxacillin sodium for injection of Tiansheng Pharmaceutical Co., Ltd
-
Last Update: 2019-01-23
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On January 22, Tiansheng pharmaceutical announced that its wholly-owned subsidiary Hunan Tiansheng Pharmaceutical Co., Ltd (hereinafter referred to as "Hunan Tiansheng") had recently received the approval document for drug registration of flucloxacillin sodium for injection (0.5g, 1.0g) approved and issued by the State Drug Administration Basic information of approval: flucloxacillin sodium is the fourth generation of half synthetic isoxacillin It was first developed by Beecham company (now affiliated to GlaxoSmithKline (GSK) Company in the United Kingdom) in the 1970s Its trade name is floxapen ®, and its dosage forms are capsule and powder injection In 2007, GSK authorized British Actavis to produce and sell floxapen ® in Europe, and changed its trade name to staphylex ® The market specifications of staphylex ® powder injection are 0.25g, 0.5g and 1.0g According to the statistics of domestic database of pharmaceutical intelligence, there are 16 market approvals for domestic flucloxacillin sodium for injection, involving 6 enterprises In addition, according to the bidding data of Yaozhi, in 2018, the average bid price of 1.0g of flucloxacillin sodium for injection was 71.29 yuan, and the average bid price of 0.5g was 39.3 yuan; the main bid winning enterprises were Sinopharm, Shanxi Zhendong Taisheng pharmaceutical and Guilin South pharmaceutical, among which Sinopharm and Shanxi Zhendong Taisheng pharmaceutical had the highest bid price, and Shanxi Zhendong Taisheng pharmaceutical had the most bid winning areas The approval of this product has not only added new varieties to its long-term focus on the field of antibiotics, but also laid the foundation for its product layout in this field The approval of this product has not only added new varieties to its long-term focus on the field of antibiotics, but also laid the foundation for its product layout in this field Source: Announcement statement of the enterprise: the viewpoint of this article only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.